NAYA Biosciences (NAYA) AI Stock Analysis

• Market Cap: $1.65M
• Dividend Yield: N/A
• Average Volume (3M): 30.30K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.53
• Revenue Growth: 390.03%
• EPS Growth: 84.00%
• Country: US
• Employees: 30
• Sector: Healthcare
• Sector Strength: 64
• Industry: Medical - Devices
• EPS (TTM): -30.54
• Shares Outstanding: 666,058
• 10 Day Avg. Volume: 74,940
• 30 Day Avg. Volume: 30,298
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 0.29
• Price to Cash Flow (P/CF): -0.70
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $2.00
• Price Target Upside: -19.35% Downside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

NAYA Biosciences' strong revenue growth is overshadowed by financial instability and lack of profitability. Technical indicators show weak performance, and valuation is unattractive. The absence of significant corporate events or earnings call insights limits positive outlook adjustments.

NAYA Biosciences Business Overview & Revenue Model

Company Description

NAYA Biosciences (NAYA) is a biotechnology company focused on the development of innovative therapies to address unmet medical needs in the oncology sector. The company leverages cutting-edge technologies to discover and develop novel drugs aimed at improving patient outcomes. With a commitment to transforming cancer treatment, NAYA prioritizes research and development to bring breakthrough therapies to market.

How the Company Makes Money

NAYA Biosciences makes money primarily through the development and commercialization of its proprietary drug candidates. The company's revenue streams include licensing agreements with pharmaceutical companies, where NAYA receives upfront payments, milestone payments, and royalties on sales of successfully commercialized products. Additionally, NAYA may engage in strategic partnerships and collaborations with other biotech firms or research institutions to co-develop and co-market therapies, thereby sharing both the costs and profits associated with bringing new drugs to market. Government grants and research funding may also contribute to NAYA's financial resources, supporting its ongoing research and development efforts.

NAYA Biosciences Financial Statement Overview

Summary

NAYA Biosciences shows strong revenue growth but struggles with profitability, leverage, and liquidity. High operational costs and financial leverage pose significant risks.

Income Statement

NAYA Biosciences shows a positive revenue growth trajectory, with a significant increase in revenue to $6.2 million in TTM (Trailing-Twelve-Months) from $3.0 million in 2023, representing a strong growth trend. However, the company faces challenges with profitability, as indicated by negative EBIT and net profit margins, with the net income remaining negative. This suggests high operational costs and inefficiencies impacting the bottom line.

Balance Sheet

The balance sheet reveals significant financial leverage concerns. With a negative stockholders' equity and a high debt-to-equity ratio, the company is highly leveraged, which poses risks. The equity ratio is negative, further indicating financial instability. The company's liabilities exceed its assets, raising concerns about its solvency.

Cash Flow

NAYA's cash flow statement indicates improvements, as evident from a reduction in negative free cash flow in the TTM compared to previous years. The operating cash flow remains negative, posing challenges for financial flexibility. However, the financing activities show inflows that partially support operations, suggesting reliance on external funding.

Breakdown
TTM	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement		Total Revenue
3.58M	3.02M	822.20K	4.16M	1.04M	1.48M
	Gross Profit
3.14M	1.09M	-28.57K	4.02M	948.53K	1.34M
	EBIT
-7.15M	-6.77M	-10.63M	-5.22M	-5.51M	-1.79M
	EBITDA
-7.41M	-6.88M	-10.75M	-5.22M	-5.48M	-1.76M
	Net Income Common Stockholders
-7.96M	-8.03M	-10.89M	-6.65M	-8.35M	-2.17M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
232.42K	232.42K	90.14K	5.68M	10.10M	1.24M
	Total Assets
18.51M	18.51M	3.71M	10.47M	10.95M	1.80M
	Total Debt
6.30M	6.30M	2.27M	2.12M	775.02K	457.47K
	Net Debt
6.07M	6.07M	2.18M	-3.56M	-9.32M	-781.12K
	Total Liabilities
17.61M	17.61M	4.69M	3.16M	5.20M	5.51M
	Stockholders Equity
892.83K	892.83K	-977.61K	7.31M	5.74M	-3.71M
Cash Flow		Free Cash Flow
-7.50M	-5.20M	-6.62M	-6.48M	-4.86M	1.31M
	Operating Cash Flow
-7.07M	-4.76M	-6.60M	-6.03M	-4.78M	1.37M
	Investing Cash Flow
-1.32M	-2.49M	-81.22K	-2.15M	-187.25K	-114.71K
	Financing Cash Flow
3.72M	7.39M	1.09M	3.77M	13.82M	-229.47K

NAYA Biosciences Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2.48
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NAYA, the sentiment is Negative. The current price of 2.48 is below the 20-day moving average (MA) of 3.16, below the 50-day MA of 4.32, and below the 200-day MA of 8.44, indicating a bearish trend. The MACD of -0.68 indicates Negative momentum. The RSI at 30.50 is Neutral, neither overbought nor oversold. The STOCH value of 36.36 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NAYA.

NAYA Biosciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	49 Neutral	$6.86B	0.72	-52.93%	2.49%	20.83%	1.11%
CRSP	46 Neutral	$3.36B	―	-19.20%	―	-89.95%	-123.71%
BLUE	42 Neutral	$36.53M	―	-270.20%	―	144.50%	-141.91%
SGMO	41 Neutral	$189.88M	―	-187.83%	―	-67.20%	64.66%
NAYA	39 Underperform	$1.65M	―	123.97%	―	390.03%	84.00%
EDIT	39 Underperform	$107.87M	―	-98.10%	―	-58.64%	-40.05%
NTLA	39 Underperform	$860.23M	―	-54.00%	―	59.55%	3.09%

NAYA Biosciences Corporate Events

NAYA Biosciences Raises $9.5M Amid Nasdaq Compliance Issues

On January 14, 2025, NAYA Biosciences completed a public offering of 13,615,171 units, raising approximately $9.5 million. The proceeds will be used for multiple strategic purposes, including funding the purchase of the Wisconsin Fertility Institute, redeeming preferred stock, addressing debt obligations, and supporting clinical trials and corporate activities. The company also received a compliance notice from Nasdaq regarding the failure to hold an annual meeting of shareholders but plans to address it by March 2025.